Solinsky Ryan, Linsenmeyer Todd A
a Spaulding Rehabilitation Hospital , Boston , Massachusetts , USA.
b Harvard Medical School , Boston , Massachusetts , USA.
J Spinal Cord Med. 2018 Sep 10;42(5):1-5. doi: 10.1080/10790268.2018.1518764.
To evaluate the role of intravesical lidocaine in preventing autonomic dysreflexia (AD) during routine catheter changes in individuals with spinal cord injury (SCI) at T6 or above.
Prospective observational cohort study.
Outpatient urology clinic.
Fifty consecutive individuals with SCI at or above T6 and a history of AD having a routine indwelling catheter change.
A treatment group of individuals received 10 ml of 2% lidocaine administered into the existing catheter 4-6 minutes prior to catheter change. The control group had the same amount of lidocaine administered into the urethra or suprapubic tract after removing the old catheter and immediately prior to inserting the new catheter (due to the delayed onset of action of the anesthetic, this was assumed to have no initial effect). Systolic blood pressures (SBP) were measured immediately after catheter insertion and then every 30-45 seconds for 5 minutes.
Incidence and magnitude of AD as determined by SBP following catheter change.
The incidence of AD in the lidocaine treatment group was 14.8% vs 47.8% in the control group (P = .011). Pretreatment with lidocaine also demonstrated a significantly attenuated rise in SBP immediately after the catheter change (9.5 mmHg vs 26.9 mmHg for post-treatment, P = .014) relative to baseline SBP.
In individuals with SCI at risk of AD, pretreatment with intravesical lidocaine prior to catheter change significantly decreased both the incidence and magnitude of AD. This suggests that pretreatment with intravesical lidocaine is helpful in individuals with SCI who are prone to AD.
评估膀胱内注射利多卡因在预防T6及以上脊髓损伤(SCI)患者常规更换导尿管期间自主神经反射异常(AD)中的作用。
前瞻性观察队列研究。
门诊泌尿外科诊所。
连续50例T6及以上脊髓损伤且有AD病史的患者进行常规留置导尿管更换。
治疗组患者在更换导尿管前4 - 6分钟经现有导尿管注入10 ml 2%利多卡因。对照组在拔除旧导尿管后且即将插入新导尿管前,将等量利多卡因注入尿道或耻骨上区域(由于麻醉起效延迟,假定此时无初始效果)。导尿管插入后立即测量收缩压(SBP),然后每30 - 45秒测量一次,共测量5分钟。
更换导尿管后通过SBP确定的AD发生率及严重程度。
利多卡因治疗组AD发生率为14.8%,而对照组为47.8%(P = 0.011)。与基线SBP相比,利多卡因预处理还显示更换导尿管后SBP立即升高幅度明显减小(治疗后为9.5 mmHg,对照组为26.9 mmHg,P = 0.014)。
对于有AD风险的SCI患者,更换导尿管前膀胱内注射利多卡因预处理可显著降低AD的发生率及严重程度。这表明膀胱内注射利多卡因预处理对易发生AD的SCI患者有帮助。